MSLN and mesothelioma: To this end, we chose to target mature human mesothelin (hMSLN, AA residues 296-606) as a therapeutically relevant cell surface antigen highly expressed in several aggressive solid tumours including mesothelioma and pancreatic adenocarcinomas33–35.